BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

31 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Targeting the Inhibition of B-Cell Lymphoma 2 Protein for the Treatment of Cancer.EBI
Therachem Research Medilab
Positive Allosteric Modulators of alpha7 Nicotinic Acetylcholine Receptor for the Treatment of Several Central Nervous System Diseases.EBI
Therachem Research Medilab
Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer.EBI
Therachem Research Medilab
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.EBI
Therachem Research Medilab
Orexin Receptor Agonists as Possible Treatment for Narcolepsy and Idiopathic Hypersomnia.EBI
Therachem Research Medilab
Dual Inhibition of IL-2-Inducible T-Cell Kinase (ITK) and Tropomyosin Receptor Kinase A (TRKA) as Potential Treatment for Atopic Dermatitis and Other Inflammatory and Autoimmune Diseases.EBI
Therachem Research Medilab
Therapeutic Potential of Monoacylglycerol Lipase (MGL) Inhibitors as Treatment for Pain, Depression, Cancers, and Eye Conditions.EBI
Therachem Research Medilab
The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.EBI
Therachem Research Medilab
Adenosine Receptor Antagonists as Potential Cancer Therapy.EBI
Therachem Research Medilab
Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists May Provide a Superior Treatment for Pain and Migraine.EBI
Therachem Research Medilab
Cannabinoid Receptor Agonists for the Potential Treatment of Pain, Neurological Disorders, Fibrotic Diseases, Obesity, and Many More.EBI
Therachem Research Medilab
The Potential of c-KIT Kinase inhibitors in Cancer Treatment.EBI
Therachem Research Medilab
Therapeutic Potential of Autotaxin Inhibitors in Treatment of Interstitial Lung Diseases.EBI
Therachem Research Medilab
Use of Dihydroorotate Dehydrogenase Inhibitors for Treatment of Autoimmune Diseases and Cancer.EBI
Therachem Research Medilab
Myeloid Cell Leukemia-1 Inhibitors as Emerging Cancer Treatment.EBI
Therachem Research Medilab
Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.EBI
Therachem Research Medilab
Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta.EBI
Therachem Research Medilab
Potential Cancer Treatment by Agonists of the Stimulator of Interferon Genes.EBI
Therachem Research Medilab
Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.EBI
Therachem Research Medilab
LRRK2 Kinase Inhibitors as Possible Therapy for Parkinson's Disease and Other Neurodegenerative Disorders.EBI
Therachem Research Medilab
Rapalogs Potential as Practical Alternatives to Rapamycin.EBI
Therachem Research Medilab
Potential of ROCK Inhibitors as Treatment for Cardiovascular Diseases, Cancer, and More.EBI
Therachem Research Medilab
Second-Generation FGFR Inhibitors for the Treatment of Cancers Harboring Mutated FGFRs.EBI
Therachem Research Medilab
Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders with GPR119 Agonists.EBI
Therachem Research Medilab
ASK1: A Therapeutic Target for the Treatment of Multiple Diseases.EBI
Therachem Research Medilab
Lysophosphatidic Acid Receptor 1 Antagonists for the Treatment of Fibrosis.EBI
Therachem Research Medilab
Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.EBI
Therachem Research Medilab
Therapeutic Potential of FXR Agonists in the Treatment of Multiple Diseases.EBI
Therachem Research Medilab
ATR Inhibitors as Potential Treatment for Cancers.EBI
Therachem Research Medilab
GPR40 Receptor Agonists for the Treatment of Type 2 Diabetes and Related Diseases.EBI
Therachem Research Medilab
Potential of PDE10A Inhibitors as Treatment for Schizophrenia and Other Neurological Disorders.EBI
Therachem Research Medilab